I don’t know of a paper that has laid this out. This is akin to the fact that you can write principal component analysis as a kind of penalized estimation. I wish I had more.
A great question. I don’t have experience with that “new baseline” design. It may be covered in @Stephen 's amazing Statistical Issues in Drug Development book or in Steve Piantadosi’s clinical trials book.